Leading Medical Organizations Update Guideline for Molecular Testing and Targeted Therapies in Lung Cancer
DENVER, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide.
To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies-the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)-have updated their 2013 evidence-based guideline.
Published today in early online release, the "Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors," continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment.
Targeted cancer therapies are drugs or other treatments that block the spread of cancer by interfering with specific molecules that spur that specific cancer's growth and progression. Patients whose tumors harbor certain, specific molecular alterations may be candidates for targeted tyrosine kinase inhibitor (TKI) therapy, which may improve survival and quality of life.
"Several factors influenced this update, which builds on the guidance we set forth in 2013," said Neal Lindeman, MD, director of Molecular Diagnostics at Brigham and Women's Hospital and Associate Professor of Pathology at Harvard Medical School in Boston, and AMP member. "Clinical practice guidelines must continually assess new evidence as it accumulates and consider new testing technologies as they emerge."
Dr. Lindeman led the international, multidisciplinary panel of expert authors appointed by each of the three organizations. The panel included pathologists, oncologists, pulmonologists, a methodologist, laboratory scientists, and patient representatives who collaborated to develop the guideline following the Institute of Medicine's evidence-based process.
The updated guideline strengthens or reaffirms the majority of the 2013 recommendations for patients with lung adenocarcinoma, and also recommends testing for some new genes. Most notably:
- Testing for ROS1 mutations is new and strongly recommended for all lung cancer patients regardless of clinical characteristics.
- Multiplexed genetic sequencing panels (e.g., NGS testing) are preferred over multiple single-gene tests to identify other treatment options beyond EGFR, ALK, and ROS1, however single gene assays are still acceptable.
- When NGS is performed, several other genes are also recommended - BRAF, ERBB2, MET, RET, and KRAS. However, these genes are not essential when only single gene tests are performed. Note: BRAF had late-breaking early evidence, which we expect to mature to a stronger recommendation for inclusion as a single gene assay, as well, in the near future.
- Testing in relapse is required for EGFR (T790M), but not for ALK, as the differential sensitivities of second-line ALK inhibitors in the setting of specific acquired mutations in ALK has not yet sufficiently matured and is still investigational.
- Testing for EGFR T790M in relapse may be done by biopsy or cell-free circulating DNA. However cell-free DNA is not appropriate for initial diagnosis at this time, unless a tissue or cytology sample cannot be obtained.
- Previous recommendations, otherwise, were largely reinforced, with some strengthening of evidence that has led to strengthening of the original recommendations. Most notable changes:
· Inclusion of IHC for ALK as an alternative to FISH;
· Inclusion of any cytology sample with adequate cancer content, as opposed to recommending cell blocks.
- Opinion is expressed that samples should also be set aside for assays to predict response to immunotherapy (e.g., PD-L1 IHC), but no specific recommendations about how to predict this treatment response were made, and will be the subject of an upcoming guideline.
The complete guideline is available online at the Archives of Pathology & Laboratory Medicine , Journal of Thoracic Oncology , and the Journal of Molecular Diagnostics . Additionally, the CAP, IASLC and AMP developed resources to help pathologists and oncologists review and implement the guideline, including a summary of recommendations, a teaching presentation, and frequently asked questions.
About the College of American Pathologists
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, READ THE CAP ANNUAL REPORT at CAP.ORG.
About the International Association for the Study of Lung Cancer
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the Association for Molecular Pathology
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,300+ members practice in the various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions and oncology. They include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. For more information, visit www.amp.org.
Kerry Lydon, CAP
Colleen Miller, IASLC
Andrew Noble, AMP
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IASLC via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Paper in Scientific Reports Highlights Ability of 4D Pharma’s MRx0004 to Protect Against Airway Inflammation in Severe Asthma14.8.2018 08:00 | Pressemelding
Data suggest that MRx0004 is a promising next-generation therapeutic for management of asthma LEEDS, United Kingdom, Aug. 14, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces the publication of a paper demonstrating that MRx0004, a live biotherapeutic derived from the human gut microbiome, can protect against airway inflammation by reducing both neutrophilic and eosinophilic infiltration in a mouse model of severe asthma. The paper “Bifidobacterium breve MRx0004 protects against airway inflammation in a severe asthma model by suppressing both neutrophil and eosinophil lung infiltration” (Raftis et al.) is published in the Nature Publishing Group journal Scientific Reports . Asthma is a phenotypically heterogeneous disease. Between 5-10 % of asthma patients have a severe form of the disease which is refractory to steroid treatment and whose symptoms cannot be controlled despite the application o
Bombardier Continues African Market Penetration with Pre-Owned Q40013.8.2018 17:19 | Pressemelding
PassionAir becomes first Bombardier operator in Ghana with three Q400 aircraft MONTREAL, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft announced today that the company successfully placed three pre-owned Q400 turboprops with PassionAir from the Republic of Ghana. The airline acquired the aircraft through a dry-lease with a third party. “Bombardier has sold about 3,500 new regional aircraft to date, and we continue to be very active on the used aircraft market.” said David Speirs, Vice President, Asset Management, Bombardier Commercial Aircraft. “Our recent momentum on the pre-owned aircraft market worldwide is a clear indication that our products are addressing a growing need for regional air transportation, especially in emerging markets.” “Our market penetration in Africa continues to intensify, and we are pleased to welcome Passion Air as the first commercial airline operating a Bombardier regional aircraft in the Republic of Ghana,” said Jean-Paul Boutibou, Vice
SEMAFO: Armed Incident in Est Region13.8.2018 17:09 | Pressemelding
MONTREAL, Aug. 13, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX, OMX: SMF) regrets to report that an armed incident occurred between the town of Fada and the Boungou Mine site in the Est region of Burkina Faso. As a result, five gendarmes and one sub-contractor employee lost their lives. Operations at the Boungou Mine were not affected. As a precautionary measure, we will be increasing our security measures and continue to closely monitor the situation with our partners to protect the safety of SEMAFO employees and our operations. The Corporation would like to express its deepest sympathy to families of the victims. About SEMAFO SEMAFO is a Canadian-based mining company with gold production and exploration activities in West Africa. The Corporation operates the Mana Mine in Burkina Faso, which includes the high-grade satellite deposit of Siou, and is targeting commercial production at the Boungou Mine in the third quarter of 2018. SEMAFO is committed to evolve in a conscientious manner to
Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer13.8.2018 14:00 | Pressemelding
NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that preliminary safety and efficacy data from a Phase 1/2 clinical trial of CK-101 (also known as RX518), a third-generation epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) being evaluated in advanced non-small cell lung cancer, has been selected for a late-breaking oral presentation at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer, to be held September 23-26, 2018, in Toronto. "We are thrilled to announce that preliminary data from the Phase 1/2 trial of our novel third-generation EGFR inhibitor has been selected for a late-breaking oral presentation at the World Conference on Lung Cancer. This marks the
Mash Group Plc reports interim unaudited financials, H1 2018 ended 30th June 201813.8.2018 08:00 | Pressemelding
Mash Group reports record H1/18 revenue, up 99% from H1/17. With H1/18 lending volumes surpassing full year 2017 and a strong EBIT of EUR 5.5 million achieved, Mash Group is extremely well positioned to continue executing on its growth plan, comments CEO Hickson . Mash continued to grow rapidly in all markets during the second quarter, achieving record lending volumes and maintaining strong momentum. Strategic Highlights Mash increases the size of its structured financing facility with funds managed by affiliates of Fortress Investment Group LLC (NYSE:FIG), from EUR 120 million to EUR 200 million. Mash was recognized as one of the Fintech50, Europe’s leading list of FinTech companies. AI Global Media, award CEO Hickson ‘Most Influential FinTech CEO of the year 2018’. Operational Highlights Mash continued to grow rapidly in all markets during the second quarter, achieving a record Q2 2018 in terms of lending volumes (+27%) and revenues (+36%) compared to Q1 2018. Registered merchants fo
ATPCO Awarded Patent for Cacheless Airline Ticket Pricing Model13.8.2018 06:00 | Pressemelding
Establishes Technology Foundational to Next-Gen Airline Revenue Management Tools DULLES, Va., Aug. 13, 2018 (GLOBE NEWSWIRE) -- ATPCO today announced that it has been awarded Patent #10,032,195 by the United States Patent and Trademark Office to cover new technology, developed by its data scientists and technical architects, that enables construction of airline ticket prices using graph database and “functional programming” techniques. This technology permits a unique approach to calculating airfare prices that was not previously available. Airline ticket prices are built using diverse individual data components: fares, flight schedules, taxes, and various legal and governance structures. An airline also sets business restrictions, known as rules, to determine under what circumstances a fare may be offered, such as requiring a Saturday-night stay or during pre-determined promotional sale dates. All these elements must be referenced and incorporated into the final price of an airline ti
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom